Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. - Wikidata - wikimedia - TriplyDB

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.

http://www.wikidata.org/entity/Q43785986

about

Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism Gemcitabine in metastatic breast cancer.Role of gemcitabine in cancer therapy.A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer.Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature.Gemcitabine in combination with paclitaxel for the treatment of metastatic breast cancer.Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer.High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.

P2860

Q33237182-B2BFA3BD-85D1-4BBD-B3D5-A7448EAAF843 Q33847161-F1C6A947-F363-45FE-970A-E371CB01C5C1 Q36185611-5DD48592-0E65-4768-90C1-5A554489E577 Q36429373-2750FB4F-FD0E-40F8-9701-C92235A0403B Q36608636-897E6F52-B2C8-4179-ABCC-72D4E3F442ED Q36615222-9BD64F00-D3CE-4D0A-BC71-0C0D19ED4467 Q36673766-CC5C0E50-48D1-4F97-A74D-0A3A0B83A019 Q36696923-7020555C-FCD6-49DD-AE26-8EE55B36277D Q37695504-099FA162-BA27-4C37-BC89-2ABAB7D83CF9 Q43267072-FE079673-4F39-4B67-BA50-28BBE4E83F69 Q44067892-324757C4-CA11-410D-ADB8-673EBCF9F2D0 Q44351257-F93073F3-D0E2-46E8-969F-ED3FC9860AA3

P2860

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.

http://www.wikidata.org/entity/Q43785986

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.

@en

Gemcitabine plus epirubicin plus taxol

@nl

type

label

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.

@en

Gemcitabine plus epirubicin plus taxol

@nl

prefLabel

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.

@en

Gemcitabine plus epirubicin plus taxol

@nl

P1433

Q43785986-5CBE1D9E-AEAE-4BB7-9561-24EFD653CCD9

P1476

Q43785986-1024B4C2-CC2F-4C55-86FD-34EC8506F353

P2093

Q43785986-10FFACF9-1D63-420F-B03C-FB32EF2D3C0A

Q43785986-30241043-EF23-43B1-9377-0A736961F9B4

Q43785986-351D6FBF-C5D0-47BD-8458-E2754AA6A9B8

Q43785986-75FD0AA1-F9D5-471E-B1E3-C2972AAB08B3

Q43785986-91F36596-1A61-496D-87DC-04826B22C652

Q43785986-9469069D-CF5E-42C9-A26E-B9A0D3B5168D

Q43785986-9D031B7F-9319-4778-A29F-FC5E14E5AED3

Q43785986-CD921CA2-B15C-4A71-AC60-082A6D2D252E

Q43785986-D42A6806-845C-4980-9016-B738BCBD9A6C

Q43785986-DA0CE34C-C194-4A7B-A8E3-C4EC3418C627

P2860

Q43785986-1F4E8F66-2AEF-4AD5-B2D7-FE6FFAD496B0

Q43785986-24217707-BFF4-458C-BA2C-EB70A5F7D5D3

Q43785986-5060D109-AF4A-455B-A04A-7A58BF94E811

Q43785986-5A8C5D68-E7C0-489B-A386-E86A74BFF769

Q43785986-71E1223F-3D4C-4CE7-857B-CBC49D679EAB

Q43785986-75D96F0D-C490-42F5-AD22-00C8EC9DFD4A

Q43785986-7D18F663-14B0-4EAB-A343-4F8275D4C4C5

Q43785986-85B02BDA-7D38-4A3A-9C09-7A3CD97EECAC

Q43785986-8B9261C4-6FD9-4AB3-83CE-3FE94CE919D3

Q43785986-C03A001A-735C-4BB5-B683-0E7327C2F2E1

P2888

Q43785986-03F9D3B6-61D3-4E6C-AF12-1C800C8DF02F

P304

Q43785986-9D0D0B07-EFFF-4F59-A41C-446684FD3E3A

P31

Q43785986-742C6E52-8542-4A6F-BB5E-2AF8A60C3D67

P356

Q43785986-B70872DE-84E0-4AC1-B06D-BF794EACAD85

P407

Q43785986-FCDC3C9B-D201-4D5B-A7B7-D7C99F25E68D

P433

Q43785986-958D7936-8E10-4DAC-A4D3-ADDE772DD27F

P478

Q43785986-951304E1-139B-4803-9DF2-24EE7F787ACD

P577

Q43785986-DA4303D5-5411-4176-A8CB-EFCBEA783305

P6179

Q43785986-96C9DD41-A031-4AC5-9B5D-15FC362A2174

P698

Q43785986-E1191FFC-A1E2-40C9-BB9B-19DB209D86F8

P356

A:1011945623464

P1433

Breast Cancer Research and Treatment

P1476

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.

@en

P2093

A Gennari

http://www.w3.org/2001/XMLSchema#string

B Salvadori

http://www.w3.org/2001/XMLSchema#string

C Bengala

http://www.w3.org/2001/XMLSchema#string

C Orlandini

http://www.w3.org/2001/XMLSchema#string

E Baldini

http://www.w3.org/2001/XMLSchema#string

I Pazzagli

http://www.w3.org/2001/XMLSchema#string

M Del Tacca

http://www.w3.org/2001/XMLSchema#string

P F Conte

http://www.w3.org/2001/XMLSchema#string

R Danesi

http://www.w3.org/2001/XMLSchema#string

S Donati

http://www.w3.org/2001/XMLSchema#string

P2860

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors

Reporting results of cancer treatment

Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.

Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study.

Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.

Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity

Advanced breast cancer: a phase II trial with gemcitabine.

5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.

Anthracyclines-paclitaxel combinations in the treatment of breast cancer.

P2888

a:1011945623464

P304

171-179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1023/A:1011945623464

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P577

2001-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1039264693

http://www.w3.org/2001/XMLSchema#string

P698

11688520

http://www.w3.org/2001/XMLSchema#string